Apotex Corp. received the FDA approval for its generic Lenalidomide on Aug. 30, expanding its portfolio to challenge competitors within the myeloma treatment market. The clearance is expected to intensify price competition and pressure pricing as additional generic entrants seek to capture market share from the branded version.